Jim Simons
IMMX icon

Jim Simons’s Immix Biopharma IMMX Stock Holding History

Jim Simons’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-258,600
Closed -$1.35M – 3454
2025
Q4 		$1.35M Buy
258,600
+237,100
+1,103% +$976K ﹤0.01% 2103
2025
Q3 		$44.9K Buy
+21,500
New +$51.6K ﹤0.01% 3352
2024
Q3 		– Sell
-154,685
Closed -$306K – 3698
2024
Q2 		$306K Sell
154,685
-110,815
-42% -$255K ﹤0.01% 2901
2024
Q1 		$815K Buy
265,500
+233,100
+719% +$903K ﹤0.01% 2613
2023
Q4 		$224K Buy
+32,400
New +$147K ﹤0.01% 3094
2023
Q3 		– Sell
-10,600
Closed -$29K – 3872
2023
Q2 		$29K Buy
+10,600
New +$22.2K ﹤0.01% 3708
2022
Q4 		– Sell
-27,050
Closed -$37K – 4247
2022
Q3 		$37K Buy
+27,050
New +$59.1K ﹤0.01% 3825
2022
Q2 		– Sell
-62,600
Closed -$151K – 4392
2022
Q1 		$151K Buy
+62,600
New +$232K ﹤0.01% 3717

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Jim Simons's IMMX Position: Q1 2026 in Review

Jim Simons sold out of Immix Biopharma (IMMX) in Q1 2026, closing a stake of 258,600 shares — an estimated $1.35M sold.

Jim Simons first reported a position in IMMX in Q1 2022 and held it in 8 quarters. The position peaked at $1.35M in Q4 2025. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Jim Simons reported no remaining Immix Biopharma position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 258,600 Immix Biopharma shares in Q1 2026, an estimated $1.35M.
  • Jim Simons first reported a position in Immix Biopharma in Q1 2022 and held it in 8 quarters.
  • Jim Simons's Immix Biopharma position peaked at $1.35M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.